J. Lear

Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study
20231 citationsauthor #1
Germline intergenic duplications at Xq26.1 underlie Bazex-Dupre-Christol syndrome, an inherited basal cell carcinoma susceptibility condition
20220 citationsauthor #28
A review of allergic contact dermatitis for dental professionals
20220 citationsauthor #10
Clinicopathological characteristics of individuals with coexisting melanoma and chronic lymphocytic leukaemia: a multicentre cohort study
20221 citationsauthor #15
A Real-World Data Study on the Healthcare Resource Use for Uncontrolled Moderate-to-Severe Atopic Dermatitis in Secondary Care in the United Kingdom Prior to the Introduction of Biologic Treatment
20222 citationsauthor #6
Germline intergenic duplications at Xq26.1 underlie Bazex–Dupré–Christol basal cell carcinoma susceptibility syndrome *
202214 citationsauthor #28
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)
202220 citationsauthor #5
Comparison of ALitretinoin with PUVA as the first-line treatment in patients with severe chronic HAnd eczema (ALPHA): study protocol for a randomised controlled trial
20225 citationsauthor #8
Female Immunity Protects from Cutaneous Squamous Cell Carcinoma
202114 citationsauthor #12
Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma
202110 citationsauthor #1
26211 Pharmacokinetics of sonidegib in patients with nevoid basal cell carcinoma syndrome
20210 citationsauthor #1
26206 Effect of sonidegib on secondary tumor size endpoints through 12 weeks of treatment in patients with nevoid basal cell carcinoma syndrome
20210 citationsauthor #1
British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021 *
202184 citationsauthor #12
Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion
2020143 citationsauthor #9
British Society for Skin Care in Immunosuppressed Individuals
202010 citationsauthor #13
16321 Investigator assessment of the efficacy of sonidegib 200 mg once daily and concordance rates with assessments by central review in patients with locally advanced basal cell carcinoma: Results of the 42-month randomized double-blind BOLT study
20200 citationsauthor #6
Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial
202015 citationsauthor #1
Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma
20202 citationsauthor #5
16334 Duration of response and progression-free survival with sonidegib 200 mg once daily until disease progression or start of new antineoplastic therapy in patients with locally advanced basal cell carcinoma
20200 citationsauthor #2
15146 Effect of concomitant common cardiovascular medications on efficacy of sonidegib 200 mg daily in patients with locally advanced basal cell carcinoma: Results of the 42-month randomized, double-blind BOLT study
20200 citationsauthor #1
Adverse Events of Special Interest in Patients with Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study
20200 citationsauthor #3
Duration of Response and Progression-Free Survival with Sonidegib 200 Mg Once Daily Until Disease Progression or Start of New Antineoplastic Therapy in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month, Randomized, Double-Blind
20200 citationsauthor #2
Effect of Concomitant Medications on Efficacy of Sonidegib 200 Mg Daily in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month Randomized, Double-Blind BOLT Study
20200 citationsauthor #6
16306 Effect of concomitant medications on efficacy of sonidegib 200 mg daily in patients with locally advanced basal cell carcinoma: Results of the 42-month randomized, double-blind BOLT study
20200 citationsauthor #6
Patient preferences for topical treatment of AK
20190 citationsauthor #6
Management of Non-melanoma Skin Cancer in Transplant Recipients.
201939 citationsauthor #4
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
2019171 citationsauthor #6
PSS44 - AN EVALUATION OF THE CURRENT TREATMENT PATHWAYS AND ASSOCIATED NHS RESOURCE USE FOR THE MANAGEMENT OF UNCONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS IN SECONDARY CARE
20182 citationsauthor #5
Patient preferences for topical treatment of actinic keratoses: a discrete‐choice experiment
201818 citationsauthor #6
139 Anti-BCC efficacy of a topical hedgehog inhibitor without adverse effects in BCNS patients in a phase 2 randomized controlled trial
20181 citationsauthor #1
Defining the actinic keratosis field: a literature review and discussion
201880 citationsauthor #5
Hedgehog pathway inhibition by topical patidegib to reduce BCC burden in patients with basal cell nevus (Gorlin) syndrome.
201829 citationsauthor #2
Photodynamic therapy corrects abnormal cancer-associated gene expression observed in actinic keratosis lesions and induces a remodeling effect in photodamaged skin.
201813 citationsauthor #10
The cost-effectiveness of 5-FU-SA in the treatment of actinic keratoses of the face and scalp in the UK secondary care setting
20175 citationsauthor #6
Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.
201732 citationsauthor #7
Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases
201742 citationsauthor #3
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
2017179 citationsauthor #1
What lies beneath actinic keratosis? Looking beyond visible lesions to optimize patient outcomes
20170 citationsauthor #1
A Novel Actinic Keratosis Field Assessment Scale for Grading Actinic Keratosis Disease Severity.
201751 citationsauthor #5
Treatment of severe, chronic hand eczema: results from a UK‐wide survey
201711 citationsauthor #10
Actinic Keratosis, a Chronic, Progressive Disease: Understanding Clinical Gaps to Optimise Patient Management.
201715 citationsauthor #5
6 Genomics of Basal and Squamous Cell Carcinomas
20170 citationsauthor #2
Emerging trends in the treatment of advanced basal cell carcinoma.
201779 citationsauthor #5
Treatment patterns and outcomes for patients with locally advanced basal cell carcinoma before availability of Hedgehog pathway inhibitors: a retrospective chart review
20175 citationsauthor #1
Patient preferences for actinic keratosis treatments: a decision choice experiment
20171 citationsauthor #7
National survey of patients with Gorlin syndrome highlights poor awareness, multiple treatments and profound psychosocial impact of disease
20163 citationsauthor #6
Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: results of the BOLT 30-month analysis
20163 citationsauthor #1
Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.
20162 citationsauthor #19
The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma
201611 citationsauthor #3
Benign Keratinocytic Acanthomas and Proliferations
20166 citationsauthor #2
Quantifying the Cost Burden of Locally Advanced Basal Cell Carcinoma on the Health Care System in the United Kingdom
20160 citationsauthor #1
Photodynamic Therapy and Non-Melanoma Skin Cancer
201663 citationsauthor #2
The European Status Quo in legal recognition and patient‐care services of occupational skin cancer
201651 citationsauthor #11
Squamous Cell Carcinoma and its Precursors
201618 citationsauthor #3
Change in Fatigue and Correlations with Clinical Outcome in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib in the Bolt Study
20160 citationsauthor #13
Prevalence, recurrence, and cost burden of locally advanced basal cell carcinoma (BCC) not amenable to surgery or radiotherapy in the UK.
20161 citationsauthor #1
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
2016165 citationsauthor #21
Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice
201616 citationsauthor #3
Non-melanoma skin cancer.
201676 citationsauthor #3
Actinic keratoses, actinic field change and associations with squamous cell carcinoma in renal transplant recipients in Manchester, UK.
201533 citationsauthor #5
Treatment with two diff erent doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma ( BOLT ) : a multicentre , randomised , double-blind phase 2 trial
20151 citationsauthor #21
Tests to assist in the diagnosis of keratinocyte skin cancers in adults: a generic protocol
201518 citationsauthor #12
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.
2015386 citationsauthor #21
Main Plenary Sessions
20150 citationsauthor #1
Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC)
201414 citationsauthor #13
Increasing capacity for skin surveillance in a transplant review clinic.
20149 citationsauthor #4
British Association of Dermatologists' guidelines for the management of onychomycosis 2014
2014186 citationsauthor #2
Lack of awareness of skin cancer among immunocompromised patients with antineutrophil cytoplasmic antibody‐associated vasculitis: a questionnaire survey
20140 citationsauthor #3
Freie Vortrage Abstrakts
20140 citationsauthor #13
Common variants modify the age of onset for basal cell carcinomas in Gorlin syndrome
201414 citationsauthor #4
Evidence-based treatment for low-risk basal cell carcinoma.
20145 citationsauthor #1
Mitigating the risk of skin cancer associated with thiopurine use.
20140 citationsauthor #2
Sunscreen adherence: proffer patient preference
20141 citationsauthor #3
Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate‐photodynamic therapy
201446 citationsauthor #5
Evidence for field cancerisation treatment of actinic keratoses with topical diclofenac in hyaluronic acid
201429 citationsauthor #4
British Association of Dermatologists' guidelines for the management of onychomycosis 2014
2014186 citationsauthor #3
Ingenol mebutate: a novel treatment for actinic keratosis
201410 citationsauthor #3
Sequential Treatment of Multiple Actinic Keratoses with Solaraze and Actikerall
20148 citationsauthor #2
LBA33RANDOMIZED, DOUBLE-BLIND STUDY OF SONIDEGIB (LDE225) IN PATIENTS (PTS) WITH ADVANCED BASAL CELL CARCINOMA (BCC)
20142 citationsauthor #18
Photodynamic therapy for actinic keratosis in organ transplant patients
201360 citationsauthor #9
Is dermatitis herpetiformis a proxy of prosperity?
20132 citationsauthor #2
Utilities for advanced basal cell carcinoma
201318 citationsauthor #4
O 02 Clinical characteristics and outcome in patients with multibacillary leprosy treated with 12 months of World Health Organization multidrug therapy multibacillary regimen : a retrospective analysis of 730 patients from India
20130 citationsauthor #1
Medical image. Systemic retinoids for recurrent keratoacanthomas.
20130 citationsauthor #2
Gorlin syndrome in the United Kingdom: a survey of patient needs, treatment availability and outcomes
20130 citationsauthor #1
Developing a standardized actinic keratosis assessment protocol
20132 citationsauthor #7
Melanoma in Organ Transplant Recipients: Incidence, Outcomes and Management Considerations
201217 citationsauthor #2
Use of Photodynamic Therapy for Treatment of Actinic Keratoses in Organ Transplant Recipients
201227 citationsauthor #3
Oral hedgehog-pathway inhibitors for basal-cell carcinoma.
201247 citationsauthor #1
Skin Cancer Prevention: Recent Evidence from Randomized Controlled Trials
20128 citationsauthor #4
The Role of Ingenol Mebutate in the Treatment of Actinic Keratoses
201221 citationsauthor #3
Genomics of Basal and Squamous Cell Carcinomas
20120 citationsauthor #2
Systemic lupus erythematosus: a pragmatic guide to current management IP63. Assessment and Management of Systemic Lupus Erythematosus in the Routine Clinic Setting
20110 citationsauthor #4
Management of high-risk squamous cell carcinoma of the skin
201139 citationsauthor #3
Non-melanoma skin cancer.
2010467 citationsauthor #2
The questionable effectiveness of sunscreen – Authors' reply
20103 citationsauthor #2
Focus on Basal Cell Carcinoma
201041 citationsauthor #3
Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma.
200924 citationsauthor #4
Clinical and Immunologic Results of a Phase II Trial of Sequential Imiquimod and Photodynamic Therapy for Vulval Intraepithelial Neoplasia
200894 citationsauthor #3
Photodynamic Therapy With Methyl Aminolevulinate for Prevention of New Skin Lesions in Transplant Recipients: A Randomized Study
2008103 citationsauthor #5

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT